Sector News

Allergan taps Pfizer oncology veteran as CMO

August 15, 2018
Life sciences

As Allergan enters a key phase for late-stage products crucial to its turnaround, it’s poached a Pfizer veteran to help bring its plans to fruition.

The Dublin drugmaker has brought on Charles Hugh-Jones, the chief medical officer at Pfizer’s oncology unit, to serve as its new senior vice president and chief medical officer, it said Monday. He’ll start his new gig this month and report to Allergan R&D head David Nicholson.

“Allergan is in a position to launch a number of important new products over the next couple of years. Charles will play a critical role in supporting the safe, effective and proper use of these innovative treatments among patients and their physicians,” Nicholson said in a statement.

The move cuts short a Pfizer stint that began just 16 months ago. Before that, Hugh-Jones spent six years at Sanofi in various roles including North American chief medical officer and head of medical affairs for U.S. oncology.

Hugh-Jones won’t be putting that oncology expertise to use at his new employer, though. Allergan focuses on other therapeutic areas, including aesthetics and central nervous system conditions, and some of its most closely watched pipeline candidates include two migraine therapeutics and a depression treatment, rapastinel.

Hugh-Jones’ role will be a crucial one, as it’s high stakes for Allergan’s pipeline right now. The drugmaker’s shares have been suffering for months, and some analysts believe it’s up to the company’s pipeline to turn things around.

And if they can’t? Allergan’s R&D ranks could see some additional personnel changes down the line, Credit Suisse analyst Vamil Divan predicted earlier this year. “Continued challenges with the pipeline could lead to further pressure to change the company’s R&D leadership,” he wrote in a note to clients.

Meanwhile, Hugh-Jones is the second big exec loss for Pfizer Oncology this year. In January, the New York pharma giant saw its global president and general manager of the unit, Liz Barrett, depart to take up the reins as CEO of Novartis Oncology.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.